Article | July 10, 2017

Total Cost of Ownership Considerations for Biopharmaceutical Manufacturing Facilities

Source: G-CON Manufacturing

By Peter Makowensky, Dennis Powers, Maik Jornitz

Total Cost of Ownership Considerations for Biopharmaceutical Manufacturing Facilities

High-volume, product-specific facilities are becoming a thing of the past, replaced by those that can expand or be relocated on-demand, handle multiple products, and shift from a centralized to decentralized model as the market dictates. This paradigm shift has led to the evolution of the modular-built and prefabricated facility-manufacturing methods, especially in relation to clean rooms. Both of these methodologies offer significant benefits — the most important of which is total cost of ownership (TCO) — when compared to traditional “stick-built” facilities. But before we assess the cost implications and ROI of all three options, let’s first look take a closer look at what each method entails.